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Case presentation
A 45-year-old white man was referred for evaluation of hypertension
and sexual impotence. His hypertension was first noted at age 23.
Before treatment, his systolic blood pressure was 164 mm Hg; the
diastolic pressure was 96 mm Hg. He had taken antihypertensive agents
intermittently for several years, and for the immediate preceding 10
years had taken clonidine, 0.15 mg daily, and chlorthalidone, 37.5 mg
daily. He was overweight in high school, and he had gradually gained
weight during the ensuing years. On at least three occasions, he had lost
as much as 25 pounds through a weight-reduction diet and exercise over
a several-month period. However, he had regained this weight within
one year each time. He had been told 3 years earlier that he had
elevated lipid levels and took gemfibrozil for approximately one year.
For the previous year, he had experienced significant problems with
impotence.
Physical examination revealed an obese white man who appeared
otherwise healthy. His height was 5 ft 9 in (175 cm) and weight 277 lb
(125.9 kg). While he was taking antihypertensive medications, his
systolic blood pressure was 138—142 mm Hg, the diastolic blood
pressure was 84—88 mm Hg, measured in both arms, and the pulse rate
was 69 beats/mm. The fundi revealed no arterial narrowing, arterio-
venous nicking, hemorrhages, or exudates. His chest was clear. Car-
diac examination revealed no murmur, rub, or gallop. The jugular
venous pressure was normal, and no peripheral edema was present. The
abdomen revealed no organomegaly, tenderness, or masses. He had
significant truncal obesity, The neurologic examination was unremark-
able.
Laboratory measurements made after overnight fasting included a
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serum glucose of 101 mg/dl; triglycerides, 1142 mgldl; total cholesterol,
222 mg/dl; and HDL cholesterol, 43 mg/dl. Repeat fasting blood glucose
was 101 mg/dl, and plasma insulin concentration was 42 U/ml; 2 hours
after a standard oral glucose load, the serum glucose was 116 mg/dl and
plasma insulin concentration was 230 U/m1. Other laboratory mea-
surements revealed a serum sodium concentration of 139 mEq/liter;
potassium, 4.9 mEq/liter; creatinine, 1.3 mg/dl; BUN, 18 mg/dl; and
plasma renin activity, 1.0 ng Al/mi/hr.
A diagnosis of obesity, hyperinsulinemia, hypertriglyceridemia, and
hypertension was made. The impotence was thought to be related to his
antihypertensive medications. These medications were tapered during a
one-week period, and he began a diet restricted in sodium chloride,
calories, and fat, as well as an exercise program. At one-month
followup, his blood pressure off medication was 128—136/84—88 mm Hg
in both arms. Blood pressure monitoring at home had revealed similar
values. Normal sexual function had returned within 2 weeks after he
discontinued taking the medications. After 2 months of followup, his
weight was 270 lbs (122.7 kg), his blood pressure off medication was
124/86 mm Hg, and laboratory studies revealed a fasting blood glucose
of 129 mg/dl, a fasting plasma insulin of 40 MU/mi, and fasting
triglycerides of 1042 mg/dl.
Discussion
DR. JOHN E. HALL (Professor and Chairman, Department of
Physiology and Biophysics, University of Mississippi Medical
Center, Jackson, Mississippi): An association between obesity
and hypertension has been recognized for more than 50 years
[1—6]. A resurgence of interest in this field has recently occurred
because of the realization that weight gain might significantly
contribute to increased blood pressure in many patients with
essential hypertension. Weight gain is also an important cause
of age-related increases in blood pressure [7].
Population studies have shown correlations between body
weight and blood pressure in normotensive as well as in
hypertensive individuals [3, 5, 61, and weight gain, even over a
relatively short period (several weeks), elevates blood pressure
in humans and in experimental animals [7—11]. In many hyper-
tensive patients, weight loss significantly decreases blood pres-
sure [11—131 and this decrease can be dissociated from reduced
sodium intake [10]. Despite the recognition that obesity and
hypertension are closely associated, the mechanisms responsi-
ble for weight-related increases in blood pressure are still
unclear. Elucidation of the causes of obesity-associated hyper-
tension has been hampered by the lack of clinical and animal
studies in which sequential changes in renal, endocrine, and
cardiovascular function have been examined during the devel-
opment of hypertension or after blockade of one or more of the
feedback systems suspected to be responsible for elevating
blood pressure. Most of our current evidence in this area comes
from anecdotal observations, as illustrated in the case presen-
tation, and from studies showing correlations between one or
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more variables and increased blood pressure in obese individ-
uals.
One possible link between weight gain and hypertension that
has recently received considerable attention is the insulin
resistance and compensatory hyperinsulinemia frequently ob-
served in obese patients [14—22]. Support for the insulin resis-
tance-hyperinsulinemia concept of hypertension comes mainly
from two types of observations. First, hyperinsulinemia, insulin
resistance, and blood pressure have been correlated in obese
and lean hypertensive patients in several studies [16—24]. Sec-
ond, insulin has been shown in multiple studies to have acute
actions on the sympathetic nervous system, the kidneys, and
the cardiovascular system that could lead to hypertension if
these effects were sustained [15, 18, 25, 26]. However, there is
still considerable debate about the quantitative importance of
insulin in contributing to hypertension, and only recently have
experimental studies directly tested the importance of hyperin-
sulinemia as a cause of hypertension.
Correlations among insulin resistance, hyperinsulinemia,
and hypertension
Multiple studies have demonstrated a positive correlation
between blood pressure and plasma insulin concentration in
obese [14, 17, 18, 20, 23] as well as in lean hypertensive patients
[24, 26]. Plasma insulin levels are elevated in patients with
essential hypertension, compared with normotensive controls
[27], although differences in body weight and age often are not
taken into consideration. Berglund et al found that untreated
hypertensive individuals tended to have a higher body mass
index, higher fasting insulin levels, and greater glucose intoler-
ance than did normotensive controls and that serum insulin
concentrations were higher in hypertensive individuals even
after correction for body weight [14]. Manicardi et al found in
age- and weight-matched obese, non-diabetic individuals with
and without hypertension that insulin resistance was greater in
obese hypertensive subjects than in obese normotensive indi-
viduals; in these studies, the plasma insulin response to an oral
glucose tolerance test was correlated with blood pressure in the
obese hypertensive group [231.
Correlations between hypertension and plasma insulin con-
centration after an oral glucose load may be independent of
obesity, glucose intolerance, and age [20]. Ferrannini and
colleagues reported that insulin-mediated whole-body glucose
uptake was reduced by 30% to 40% in lean hypertensive
patients, compared with normotensive controls, thereby sug-
gesting an association between insulin resistance and blood
pressure even in non-obese individuals [24]. The severity of
hypertension in these studies was correlated with the degree of
insulin resistance as determined by the glucose infusion rates
needed to maintain euglycemia during insulin infusion. These
and other studies demonstrating a positive association among
hyperinsulinemia, insulin resistance, and hypertension have led
to considerable speculation about cause-and-effect relation-
ships among these variables.
Not all hypertensive patients, however, are insulin resistant,
and many individuals with hyperinsulinemia and insulin resis-
tance do not have high blood pressure [28, 29]. For example,
Mbanya and coworkers found that insulin levels were similar in
nondiabetic hypertensive and nondiabetic normal subjects and
that even though obese subjects had higher plasma insulin
levels, a good correlation did not exist between hypertension
and hyperinsulinemia; in fact, they found a tendency toward a
negative correlation between plasma insulin and blood pressure
[29]. Grugni et al also noted no correlation between insulin and
blood pressure in a study of 100 obese hypertensive patients
and 78 obese normotensive subjects [30]. Asch et al found that,
after stratification for obesity and glucose intolerance, no
significant difference existed between the mean age-adjusted
fasting or post-challenge insulin levels of normotensive and
hypertensive subjects [31]. Others also have reported that the
relationship between plasma insulin concentration and blood
pressure is weak [32—341 or nonexistent [35].
A dissociation between hyperinsulinemia and hypertension
also has been demonstrated in large-scale epidemiologic studies
[36, 37]. In Pima Indians and Mexican Americans in the United
States, insulin resistance and hyperinsulinemia are common,
but hypertension is rare [26, 28, 36]. Also, an inconsistent
relationship was found between insulin and blood pressure in
three different Pacific island populations [37].
Thus, considerable controversy remains about whether hy-
pertension is even correlated with plasma insulin concentration
or insulin resistance, The fact that the relationship among these
variables has not always been consistent suggests that a reas-
sessment of their interactions is warranted. Certainly, if hyper-
tension and hyperinsulinemia or insulin resistance are related,
the relationship is not a straightforward one. Moreover, the
presence or absence of an association does not prove or
disprove causality.
Because hypertension affects many organ systems and cell
functions that might or might not be involved in raising blood
pressure, it is possible that hyperinsulinemia and insulin resis-
tance occur via the multiple changes that develop secondary to
hypertension. Thus, correlations among hyperinsulinemia, in-
sulin resistance, and hypertension could have several explana-
tions: (1) hyperinsulinemia and insulin resistance could be
secondary to other abnormalities associated with hypertension;
(2) insulin resistance and hyperinsulinemia could cause hyper-
tension; and (3) insulin resistance, hyperinsulinemia, and hy-
pertension might occur through parallel but unlinked mecha-
nisms. Regardless of whether insulin and blood pressure are
correlated, the quantitative importance of hyperinsulinemia and
insulin resistance in causing hypertension clearly cannot be
established solely from correlational studies.
Are insulin resistance and hyperinsulinemia
secondary to hypertension?
Recently, insulin resistance and compensatory hyperinsulin-
emia in hypertension have been postulated to be due to vascular
rarefaction and increased peripheral vascular resistance, which
are believed to reduce the delivery of glucose and insulin and to
impair skeletal muscle uptake of glucose [38, 39]. At first
glance, this concept is intuitively pleasing when considered
only at the microcirculatory level. Hypertension almost invari-
ably is associated with increased total peripheral resistance,
and vascular rarefaction is common with longstanding hyper-
tension [40—44]. Also, it is almost certain that altered blood flow
and substrate delivery are important determinants of glucose
uptake under acute conditions, such as during transients of
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glucose disposal after a carbohydrate meal or during a glucose
tolerance test. However, it is important that we keep in mind
the chronic nature of hypertension and insulin resistance,
entities that are found under long-term steady-state conditions,
not simply when the system is challenged acutely. For this
hypothesis of insulin resistance to be valid, at least two condi-
tions must be met: (1) tissue blood flow must be reduced
chronically at the principal site at which insulin resistance
occurs, likely skeletal muscle [45, 46], and (2) sustained de-
creases in tissue (skeletal muscle) blood flow must impair
glucose uptake.
The question of whether tissue blood flow is reduced in
hypertension has generated considerable controversy. Al-
though vascular resistance usually is elevated in hypertension,
it does not necessarily follow that tissue blood flow is reduced.
In fact, vascular rarefaction and other regulatory adjustments
that raise peripheral vascular resistance might be compensatory
responses that prevent overperfusion of the tissues in hyper-
tension [40, 47]. According to this concept, increased peripheral
vascular resistance maintains substrate supply to the tissues at
a level that matches metabolic demands, even in the presence of
increased blood pressure, which tends to raise tissue blood
flow.
The literature supports this concept; most hypertensive sub-
jects have normal cardiac output and normal blood flow in the
tissues that have been studied, including skeletal muscle [40,
47]. Also, in many of the experimental studies in which vascular
rarefaction has been demonstrated, abnormalities of renal func-
tion precede the hypertension and are associated with either
blood volume expansion or reductions in venous compliance
and accompanying increases in "effective" blood volume [40,
47, 48]. In these instances, vascular rarefaction might be a
compensation for an initial overperfusion of the tissues. As
Cowley recently noted, structural rarefaction is often preceded
by functional changes that lead to increased vasomotion, de-
creased luminal diameter, and decreased maximal vasodilation,
all of which cause a functional rarefaction [40]. These functional
and anatomic changes in vascular resistance, however, do not
result in underperfusion of tissues but instead protect the
tissues from excessive blood flow or increased wall tension [40,
47, 48].
The second assumption of the hemodynamic hypothesis of
insulin resistance is that reductions in tissue blood flow impair
insulin's action on glucose uptake. But experimental evidence
and theoretical reasons suggest that changes in tissue blood
flow are not the primary mechanism by which chronic insulin
resistance occurs. First, considerable evidence indicates that
insulin resistance is due mainly to postreceptor abnormalities in
obese hypertensive patients [49]. Although insulin-receptor
binding can be altered in some pathophysiologic conditions,
reduced numbers of receptors or decreased receptor affinity for
insulin probably do not play a major role in most cases of insulin
resistance [49]. The primary reason for this is that only a small
fraction of the total number of insulin receptors normally
available is required to exert a near-maximal effect of insulin on
glucose transport [49].
Because abnormalities of insulin sensitivity associated with
hypertension and type-Il diabetes are likely to be caused by
postreceptor alterations of intracellular signaling, envisioning a
mechanism by which changes in tissue blood flow or hyperten-
sion per se could induce these abnormalities is difficult. Recent
studies investigating several forms of hypertension associated
with increased peripheral vascular resistance and vascular
rarefaction, such as renovascular or mineralocorticoid hyper-
tension, found no evidence of insulin resistance [50—53]. These
observations suggest that, in most instances, hyperinsulinemia
and insulin resistance are not a consequence of hypertension
and its associated increases in total peripheral vascular resis-
tance and blood vessel rarefaction. This conclusion agrees with
recent observations by Capaldo and colleagues, who found that
insulin resistance occurred in skeletal muscle of patients with
essential hypertension even though blood flow was not reduced
[54].
Does hyperinsulinernia cause hypertension?
Given that correlations among insulin resistance, hyperten-
sion, and hyperinsulinemia do not appear to be explained by
hypothesizing that hypertension causes insulin resistance, we
must consider the possibility that insulin resistance and com-
pensatory hyperinsulinemia cause hypertension.
Acute effects of insulin on renal, sympathetic, and cardio-
vascular function. One line of evidence that supports a role for
insulin in causing hypertension is that insulin has acute effects
on the kidneys, sympathetic nervous system, and cardiovascu-
lar system, which, if sustained, could lead to high blood
pressure. Hyperinsulinemia is widely believed to occur as a
compensation for insulin resistance in peripheral tissues, espe-
cially skeletal muscle. Normal sensitivity to insulin, however,
can be present in certain tissues, such as the kidneys and
sympathetic nervous system, in which insulin has been postu-
lated to exert effects that could increase blood pressure [55,
58—62]. Two mechanisms are often suggested by which hyper-
insulinemia might raise blood pressure: (1) by directly causing
renal sodium retention, and (2) by increasing sympathetic
nervous system activity [15, 55, 59—62].
Several studies have shown that insulin reduces sodium
excretion when administered to intact animals and humans. As
far back as the 1930s, Atchley and coworkers reported a
marked reduction in sodium excretion during reinstitution of
insulin therapy in diabetic subjects and that withdrawal of
insulin therapy increased sodium excretion [63]. Other investi-
gators have reported antinatriuresis after insulin administration
in diabetics as well as in normal and obese subjects [64, 65].
Although the exact mechanisms of insulin-mediated antina-
triuresis are not entirely clear, several studies suggest that
insulin directly increases renal tubular sodium reabsorption.
First, insulin infusion reduces sodium excretion in isolated
kidneys with no change in glomerular filtration rate (GFR) [66].
Also, intrarenal insulin infusions at rates that do not markedly
alter systemic plasma insulin concentration reduce sodium
excretion without altering GFR [67, 68]. Micropuncture studies
suggest that insulin increases sodium reabsorption at a site
beyond the proximal tubule, possibly in the ioop of Henle [69].
Insulin also has been reported to stimulate fluid reabsorption in
isolated proximal tubules, however [70].
If insulin's antinatriuretic effect were maintained chronically,
blood pressure would rise because of renal sodium retention
and extracellular fluid volume expansion. As arterial blood
pressure increased, the antinatriuretic effects of insulin would
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be offset by pressure natriuresis and, under steady-state condi-
tions, sodium balance would be maintained at the expense of
volume expansion and hypertension. Although this concept
offers an attractive explanation for the link between insulin and
blood pressure, evidence supporting it is derived mainly from
acute studies. Until recently, it was not clear whether insulin
could cause sustained reductions in renal excretory capability
sufficient to elevate blood pressure, or whether other compen-
satory mechanisms might override the antinatriuretic effect of
insulin in the absence of hypertension. Several recent studies in
our laboratory suggest, however, that insulin's antinatriuretic
effects on the kidney are not sufficient to elevate blood pressure
chronically [71]. I will return to these studies in a moment.
Another mechanism by which insulin might elevate blood
pressure is by activation of the sympathetic nervous system [18,
25, 59—61]. Troisi et al reported that total caloric intake was
independently correlated with 24-hour urinary norepinephrine
excretion in 572 men in the Normative Aging Study [72].
Increased caloric intake in rats raises sympathetic nervous
system activity and plasma insulin concentration in parallel,
whereas caloric restriction lowers plasma insulin and sympa-
thetic activity as assessed by indirect methods such as tissue
norepinephrine turnover [18, 25]. Experimental hypertension in
rats, caused by feeding a high sucrose diet, also is associated
with increased catecholamine secretion and hyperinsulinemia
[73]. It is difficult to determine from these "overfeeding"
studies, however, whether hyperinsulinemia is the key factor in
elevating blood pressure and adrenergic activity, or whether
other mechanisms are more important.
Only a few studies have directly examined the acute effects of
hyperinsulinemia on blood pressure and adrenergic activity.
Acute insulin infusion has been reported to elevate plasma
norepinephrine even when plasma glucose concentration was
held constant [74, 75], and blockade of adrenergic activity
attenuated the rise in blood pressure associated with insulin
injection [76]. The relevance of these observations to the
problem of chronic hypertension is difficult to assess, however,
as large pharmacologic doses of insulin were used and only the
acute changes in blood pressure were studied.
Anderson and colleagues recently studied the short-term
effects of pathophysiologic levels of insulin on sympathetic
nervous system activity, blood pressure, and vascular resis-
tance in humans. An increase in insulin concentration from 8 to
72—144 sU/ml in these studies increased skeletal muscle sym-
pathetic activity and plasma norepinephrine concentration but
decreased forearm vascular resistance and failed to increase
blood pressure [77]. This study indicates that in normal hu-
mans, acute (60-minute) elevations in plasma insulin exert both
pressor (increased sympathetic nervous system activity) and
depressor (vasodilator) actions, but cause little change in blood
pressure. Rooney et al also found that acute insulin infusion at
rates that raised plasma insulin concentration from 5 to approx-
imately 31 and 55 U/ml increased plasma renin activity,
plasma angiotensin II, and norepinephrine concentration, but
caused only small (2—4 mm Hg) increases in systolic blood
pressure; diastolic blood pressure was not significantly altered
by insulin infusion and, although mean arterial pressure was not
reported in the study, it is unlikely that it changed significantly
[78]. Thus, human studies indicate that relatively large in-
creases in plasma insulin concentration have little or no acute
effect on arterial pressure, although sympathetic nerve activity
can increase. Whether sympathetic activity is stimulated with
chronic hyperinsulinemia, however, has not been reported.
Thus, acute hyperinsulinemia reduces urinary sodium excre-
tion and activates the sympathetic nervous system, and these
effects, if sustained, could influence the cardiovascular system
and blood pressure regulation. Insulin also has important va-
sodilatory actions that tend to lower blood pressure, however.
The net effect of insulin on these various systems acutely raises
blood pressure only with supraphysiologic concentrations in
normal animals and humans. More important, the relevance of
these observations (made during short-term insulin administra-
tion) to the problem of chronic obesity-induced hypertension is
difficult to ascertain because the data do not indicate the
time-dependence of these various actions and whether the
alterations are sustained sufficiently to cause chronic hyperten-
sion.
Chronic hyperinsulinemia and blood pressure regulation.
Even though multiple studies have examined the acute renal
and cardiovascular actions of insulin, only a few studies have
looked at the chronic effects of insulin on blood pressure.
Because hypertension is a disturbance of long-term blood
pressure regulation, the importance of various neurohumoral
mechanisms cannot always be extrapolated from the results of
acute experiments. A pertinent example of this problem comes
from extrapolation of acute studies with vasoconstrictors such
as vasopressin to the problem of chronic hypertension. Vaso-
pressin, one of the most powerful vasoconstrictors in the body,
has been demonstrated to be important in the acute regulation
of blood pressure, particularly in circumstances such as hem-
orrhage [79]. But chronic increases in plasma vasopressin
concentrations cause only small elevations in blood pressure as
long as renal function is not impaired [80, 81]. Thus, the acute
effects of this hormone on blood pressure regulation do not
accurately predict its role in chronic hypertension. Likewise, an
understanding of the quantitative importance of insulin in
hypertension will likely come from long-term, rather than
acute, studies.
Recently we performed a series of studies in dogs and rats to
test directly whether a cause-and-effect relationship exists
between hyperinsulinemia and hypertension. These experi-
ments were designed to determine whether chronic increases in
plasma insulin concentration, comparable to those found in
obese hypertensive patients, would cause sustained increases in
blood pressure or sustained alterations in renal function [82—
85]. In one series of experiments (Fig. 1), we infused insulin into
dogs for 7 days at a rate that increased plasma insulin concen-
tration approximately five- to sixfold; plasma glucose concen-
tration was maintained relatively constant with a glucose-clamp
procedure [83]. Insulin infusion transiently reduced sodium
excretion and urine volume for 2 to 3 days, but these variables
returned toward control during the next few days; after 7 days
of insulin infusion, we noted a net retention of approximately
120 mEq of sodium. Consistent with the results from acute
studies, the sodium retention observed during hyperinsulinemia
was clearly due to increased tubular reabsorption, since GFR
and filtered sodium load, as well as effective renal plasma flow,
actually increased by approximately 15% to 20%. Despite the
transient sodium retention, mean arterial pressure fell by ap-
proximately 10 mm Hg during chronic hyperinsulinemia (Fig.
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Fig. 1. The effects of insulin infusion (1.0 U/
kg/mm, iv) for 7 days in normal dogs.
(Adapted with permission from Ref. 83.)
1). The sodium retention associated with hyperinsulinemia
might be oue, in part, to the fall in blood pressure caused by
peripheral vasodilation. Infusion of insulin for 7 days in normal
dogs markedly reduced total vascular resistance and raised
cardiac output 30% to 40% [841. Thus, sustained increases in
plasma insulin concentration caused marked peripheral vasodi-
lation, possibly due to stimulation of tissue glucose uptake and
metabolic rate and subsequent activation of local vasodilator
mechanisms. Studies in humans also suggest that acute insulin
infusion causes peripheral vasodilation associated with in-
creased metabolic rate in skeletal muscle [77, 86]. The most
important finding in this group of studies, however, is that
chronic hyperinsulinemia did not elevate blood pressure in
normal dogs [83, 84].
Blood pressure responses to chronic hyperinsulinemia after
impairment of rena/function. Although insulin infusion did not
raise blood pressure in normal dogs, we considered the possi-
bility that hyperinsulinemia might contribute to hypertension in
circumstances associated with impairment of renal function or
with an elevated intake of sodium [82]. Hypertension caused by
other antinatriuretic hormones, such as aldosterone, is mark-
edly exacerbated by high sodium intake or decreased renal
function due to loss of nephrons [47, 48]. This possibility has
clinical relevance because many obese hypertensive patients
are also elderly and because the number of functional nephrons
gradually decreases with aging, particularly after age 40 [87].
Figure 2 depicts the effects of chronic hyperinsulinemia in
dogs in which renal mass was reduced surgically to approxi-
mately 30% of normal. In these experiments, the dogs were fed
a high-sodium diet to increase their susceptibility to any poten-
tial hypertensive effects of insulin, and plasma insulin concen-
tration was increased four- to sixfold for 28 days to allow
sufficient time for insulin to exert a hypertensive effect [82],
Plasma glucose concentration was held constant with the glu-
cose-clamp procedure. Although insulin infusion transiently
decreased sodium excretion, arterial pressure did not rise; in
fact, arterial pressure decreased approximately 10 mm Hg
during insulin infusion; the changes were similar to those
observed in normal dogs. After 2 to 3 weeks of hyperinsuline-
mia, blood pressure gradually increased toward control, possi-
bly as a result of sodium and water retention that might be due,
in part, to the fall in renal perfusion pressure. The fact that there
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Fig. 2. The effects of insulin infusion (1.0 jU/
kg/mm, iv) for 28 days in dogs with reduced
renal mass maintained on a high sodium
intake of approximately 319 mEqiday.
(Adapted with permission from Ref. 82.)
was a transient overshoot of blood pressure after the insulin
infusion was stopped suggests that insulin might have been
exerting a depressor effect throughout the 28 days of the
infusion (Fig. 2). Thus, chronic hyperinsulinemia, lasting at
least 4 weeks, does not elevate blood pressure in dogs even
when renal mass is reduced and a high-sodium intake is
maintained.
Does insulin interact with other pressor stimuli to cause
hypertension? Although the studies I have cited provide no
evidence that hyperinsulinemia per se causes hypertension, it is
possible that insulin could increase the blood pressure actions
of other pressor stimuli, such as increased angiotensin II (All)
or elevated adrenergic activity. Previous acute studies in dogs
suggested that insulin potentiates the blood pressure- and
aldosterone-stimulating effects of All [88], although studies in
humans have not confirmed this observation [89]. In addition,
evidence points to increased activity of the renin-angiotensin
system and increased sympathetic activity in obese patients and
in obese dogs [18, 25, 90, 91].
Figure 3 illustrates results from experiments designed to test
the possibility that hyperinsulinemia might exacerbate the
chronic blood pressure effects of All. In these studies, renal
mass was reduced to approximately 30% of normal, the dogs
were maintained on a high sodium intake, and All was infused
at a rate that produced mild hypertension for several days
before the insulin infusion was started. Subsequent infusion of
insulin for 28 days, while maintaining All infusion constant, did
not change arterial pressure further [82]. These studies suggest
that insulin does not potentiate the chronic hypertensive effect
of All.
Although previous acute studies suggest that hyperinsuline-
mia increases plasma catecholamines, we found no indication of
increased plasma norepinèphrine or epinephrine concentration
during chronic hyperinsulinemia in normal dogs as long as
plasma glucose concentration was held constant [83]. In addi-
tion, we found no indication that insulin potentiates the chronic
hypertensive effect of norepinephrine [83]. However, we did
observe increases in heart rate during chronic hyperinsulinemia
in dogs [83, 84]; our findings are consistent with the possibility
that insulin increases sympathetic activity. Yet the mechanisms
responsible for the tachycardia during hyperinsulinemia are still
unclear and could be related to a direct chronotropic effect on
the heart, withdrawal of parasympathetic tone, or increased
sympathetic activity. Further studies are needed to explore
these possibilities. The most important conclusion from these
studies, however, is that hyperinsulinemia does not appear to
potentiate the chronic blood pressure effects of other pressor
stimuli such as All or catecholaminés.
Can chronic hyperinsulinemia cause hypertension by stimu-
lating vascular smooth muscle growth? Chronic hyperinsuline-
mia also might have a mitogenic action on vascular smooth
muscle [46, 55]. High levels of insulin induce proliferation of
cultured smooth muscle cells [93, 94]. Whether insulin, at
concentrations similar to those found in obese hypertensives,
can stimulate blood vessel growth in vivo is still not clear,
however. Also, for insulin to stimulate vascular smooth muscle
growth in insulin-resistant subjects, the blood vessels would
have to remain sensitive to the effects of insulin on cell growth
or proliferation. More important, stimulation of blood vessel
growth in peripheral tissues probably is not by itself an impor-
tant cause of chronic hypertension, because increased total
peripheral resistance does not appear to be a sufficient stimulus
for chronic hypertension.
Increased peripheral vascular resistance probably occurs
secondary to increased blood pressure in many forms of hyper-
tension [47, 48]. Numerous theoretical and experimental studies
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Fig. 3. The effects of insulin infusion (1.0 pill
kg/mm, iv) for 28 days in dogs with reduced
renal mass maintained on a high sodium
intake of 300 mEqiday and infused with
angiotensmn II (2.0 ng/kg/,nmn). Angiotensin II
infusion was started several days before
insulin infusion was begun and was continued
throughout the experiment. (Adapted with
permission from Ref. 82.)
suggest that chronic hypertension can occur only if renal
function is abnormal and a shift of the renal pressure-natriuresis
relationship occurs [46, 47]. In the absence of altered pressure
natriuresis, increased peripheral vascular resistance leads only
to a transient increase in blood pressure, as the rise in pressure
is associated with increased urinary sodium excretion, a pro-
gressive reduction in extracellular fluid volume and, eventually,
a return of arterial pressure toward normal [47, 481. For
hypertension to occur and for sodium balance to be maintained,
a requirement that is essential for life, there must be a shift of
renal pressure natriuresis so that normal rates of sodium
excretion can be maintained at elevated arterial pressures [47,
48]. Thus, stimulation of smooth muscle growth could cause
hypertension only if it also increased renal vascular resistance
and shifted pressure natriuresis to higher levels. An important
observation that argues against this possibility is the finding that
renal blood flow is increased rather than reduced in obese,
insulin-resistant subjects [90, 95]. Thus, even though the long-
term effects of hyperinsulinemia on blood vessel growth have
not been adequately studied (comparable to that found in obese,
insulin-resistant subjects), it seems unlikely that this action is a
major cause of hypertension.
Species variations in blood pressure responses to chronic
hyperinsulinemia. Although several chronic studies in dogs do
not support the concept that hyperinsulinemia is a primary
cause of obesity-induced hypertension, it might be premature to
rule out a role for insulin; species might vary in their blood
pressure responses to hyperinsulinemia. Recent studies by
Brands et al in our laboratory have shown that hyperinsuline-
mia increases blood pressure in rats [85, 961, In these studies,
arterial pressure was monitored 24 hours a day, and plasma
glucose concentration was held constant using the glucose-
clamp procedure [96]. Chronic hyperinsulinemia significantly
raised mean arterial pressure. The increased blood pressure
was not associated with sodium retention or activation of the
renin-angiotensin system [96]. These observations contrast with
findings in obesity-associated hypertension, which is character-
ized by marked sodium retention and increased plasma renin
activity [11, 62, 90—92]. In addition, rats with insulin-induced
hypertension are not sensitive to changes in sodium intake [96]
(Fig. 4), whereas obese humans with hypertension are sensitive
to alterations in soaium intake [11, 62]. Thus, insulin elevates
blood pressure in rats via mechanisms that are still unclear, but
several important differences exist between this model of hy-
pertension in rats and obesity-induced hypertension in humans.
It is still unclear whether the human blood pressure response
to insulin is more closely related to that in dogs or in rats. Acute
insulin infusion in humans causes many of the same changes
observed during insulin infusion in dogs, including peripheral
vasodilation, increased heart rate, increased plasma renin ac-
tivity, and little or no change in arterial pressure. Although
long-term insulin infusion studies in humans have not been
reported, the chronic hyperinsulinemia and insulin resistance
associated with insulinoma do not elevate blood pressure in
humans [97—99].
Several population studies have shown a poor correlation
between blood pressure and plasma insulin concentration in
normal humans [26, 28—30]. In a study of more than 2000
subjects, Ferrannini et al reported that, after adjustment for
age, sex, body-mass index, and waist:hip circumference ratio,
the slope of the regression line for blood pressure versus insulin
concentration predicted that a 200 U/ml increase in insulin
could account for only a 1 mm Hg rise in blood pressure (Fig. 5)
[26]. Considering the fact that fasting plasma insulin concentra-
tion is usually elevated by less than 20 U/ml in obese hyper-
tensive subjects compared with normal subjects [11, 16, 17, 28],
these observations call into question the quantitative impor-
tance of hyperinsulinemia in human hypertension. Although
these findings do not completely rule out the possibility that
hyperinsulinemia could interact with another, as yet unknown,
abnormality to increase blood pressure in obesity, these results
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do suggest that the independent effects of insulin on blood
pressure are minimal in humans.
Possible role of insulin resistance in hypertension
Although hyperinsulinemia per Se, comparable with that
found in obese individuals, does not appear to elevate blood
pressure in dogs or in humans with insulinoma, it is possible
that insulin resistance elevates blood pressure by facilitating a
hypertensive action of insulin or by mechanisms that are
independent of hyperinsulinemia. Several investigators have
postulated that resistance to the metabolic and cell-membrane
effects of insulin is a key element in linking obesity and
hypertension.
Because normal humans and dogs are sensitive to the effects
of insulin on glucose uptake, insulin infusion would be expected
to increase peripheral glucose uptake and metabolic rate,
changes that cause peripheral vasodilation via local blood flow
control mechanisms. Recent studies in our laboratory by
Brands et al have demonstrated that chronic hyperinsulinemia
in normal dogs markedly reduces total peripheral vascular
resistance and increases cardiac output [84]. In normal humans
and in patients with borderline hypertension, hyperinsulinemia
also reduces forearm vascular resistance and increases blood
flow [77, 100]; this response is substantially attenuated in obese,
insulin-resistant subjects [861. Therefore, some investigators
have suggested that the failure of chronic hyperinsulinemia to
elevate blood pressure in normal animals and humans could be
due to offsetting effects of peripheral vasodilation, which would
tend to lower blood pressure, and other actions of insulin (for
example, antinatriuresis and sympathetic activation), which
would tend to elevate blood pressure.
If, by preventing the peripheral vasodilatory actions of insu-
lin, insulin resistance were important in allowing the putative
hypertensive actions of insulin to be expressed, one would
predict that hyperinsulinemia would cause hypertension in
circumstances in which the peripheral vasodilatory actions of
insulin are absent. To test this hypothesis, we investigated the
effects of chronic insulin infusion into the renal artery of
conscious dogs to determine whether the direct renal actions of
insulin could cause hypertension in the absence of any periph-
eral vasodilatory effects [101]. In these experiments, we calcu-
lated insulin infusion rates to increase intrarenal, but not
systemic, insulin concentrations to levels comparable to those
found in obese hypertensive subjects [loll. Presumably, if the
direct renal actions of insulin can cause chronic hypertension,
then raising intrarenal levels should elevate blood pressure in
the absence of marked increases in systemic insulin concentra-
tions. However, intrarenal insulin infusion for 7 days failed to
significantly alter mean arterial pressure and caused only tran-
sient, mild sodium retention [loll. These observations indicate
that the direct renal actions of hyperinsulinemia, in the absence
of a peripheral vasodilatory effect, cannot cause sustained
hypertension in conscious dogs.
To further test the importance of insulin resistance as a
determinant of whether insulin can elevate blood pressure, we
examined the effects of chronic hyperinsulinemia in obese dogs
that were resistant to the metabolic effects of insulin [102]. In
these experiments, we gave dogs a high-fat diet for 6 weeks to
cause obesity, increased blood pressure, and insulin resistance.
Subsequent infusion of insulin for 7 days in obese dogs pro-
duced no significant changes in cardiac output or total periph-
eral vascular resistance. This finding contrasts with the re-
sponse of normal dogs, in which total peripheral resistance
decreased and cardiac output increased markedly [841. Thus,
compared with normal dogs, obese dogs are resistant to the
peripheral vasodilatory and metabolic actions of insulin. Yet,
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despite insulin resistance, blood pressure did not increase
significantly in obese dogs infused with insulin [1021. In fact,
insulin infusion caused a small decrease in blood pressure, an
alteration similar to that found in normal dogs. Thus, the
presence of insulin resistance does not appear to markedly alter
the blood pressure responses to chronic hyperinsulinemia in
dogs.
Insulin resistance has been postulated to play a key role in
hypertension not only by causing compensatory hyperinsuline-
mia, but also by other, as yet unidentified, mechanisms that
increase peripheral vascular resistance [58, 59, 103, 104]. For
example, insulin resistance might elevate intracellular calcium
concentration in vascular smooth muscle, thereby causing
peripheral vasoconstriction and increased blood pressure [103].
This notion is based on the observation that insulin blocks
calcium currents, shortens calcium-driven action potentials,
and causes cell membrane depolarization and relaxation in
normal vascular smooth muscle [103]. Insulin also might atten-
uate the contractile response of vascular smooth muscle to
constrictor agents and stimulate calcium-ATPase activity [103],
in turn lowering intracellular calcium concentration. Presum-
ably, in tissues that are insulin resistant, these actions of insulin
are blunted, causing increased intracellular calcium concentra-
tion. In support of this possibility are recent studies showing
that intracellular calcium concentration is elevated in vascular
smooth muscle of insulin-resistant animals such as the Zucker
obese rat [103]. We should remember, however, that correla-
tions between insulin resistance in these models of obesity and
cell transport abnormalities do not prove cause-and-effect rela-
tionships. It is still not clear to what extent insulin resistance
contributes to these changes or whether alterations in ion flux at
the cell membrane may be caused by other cellular defects
unrelated to insulin resistance.
An observation that argues against the hypothesis that a
primary increase in total peripheral resistance, initiated by
insulin resistance, is a major factor in causing obesity-induced
hypertension is the finding that cardiac output is elevated and
that in many tissues blood flow is increased, rather than
reduced, in obese hypertensive patients [105, 106]. Experimen-
tal models of hypertension associated with vasoconstriction
usually are characterized by normal or reduced cardiac output
and tissue blood flow [47, 48], rather than by increases, as in
obesity [105, 106].
Other theoretical considerations and experimental observa-
tions also argue against an increase in total peripheral vascular
resistance as a primary cause of hypertension. Although in-
creased total peripheral resistance is a hallmark of most forms
of established hypertension, numerous studies have suggested
that increased peripheral vascular resistance is unlikely to
initiate the hypertension unless the constriction also occurs in
renal vessels and shifts pressure natriuresis to higher blood
pressures [47]. A key element in all experimental forms of
hypertension studied thus far, including human essential hyper-
tension, is an abnormality of renal function that shifts pressure
natriuresis to higher blood pressures [47, 107, 108].
If insulin resistance also caused vasoconstriction in renal
vessels and shifted pressure natriuresis to higher levels, hyper-
tension would result [47, 107]. Recent studies indicate, how-
ever, that obesity and insulin resistance are not associated with
renal vasoconstriction [90]. In fact, renal blood flow and GFR
increase markedly in obese, insulin-resistant dogs [90]. These
observations suggest that increased peripheral vascular resis-
tance mediated by insulin resistance probably is not a primary
factor in causing hypertension in obese individuals.
Abnormal renal function in obesity-induced hypertension
Rocchini et al reported that the pressure-natriuresis curve
was altered in obese adolescents [11]. Figure 6 shows the
steady-state relationships between blood pressure and sodium
excretion for normal individuals, obese adolescents, and the
same subjects after they lost weight. In normal subjects, the
relationship is extremely steep, whereas in obese individuals
the slope of the curve is reduced, an abnormality corrected by
weight loss. Although the mechanisms responsible for altered
pressure natriuresis in obese subjects have not been elucidated,
increased tubular sodium reabsorption or an inability to sup-
press All formation in response to volume expansion appears to
initiate elevated blood pressure in many forms of hypertension
associated with a reduced slope of the pressure-natriuresis
relationship. Obesity-induced hypertension thus might be
caused by factors that increase renal tubular sodium reabsorp-
tion or prevent All formation from being suppressed in re-
sponse to volume expansion.
We found in preliminary studies that obesity-induced hyper-
tension in dogs was associated with increased sodium reabsorp-
tion at a nephron site beyond the proximal tubule [90, 109]. The
increased reabsorption was accompanied by marked sodium
retention, large increases in GFR and renal plasma flow,
expansion of extracellular fluid volume, and a failure to sup-
press plasma renin activity [90, 109]. Although hyperinsuline-
mia cannot account for these changes in obese dogs, the basic
mechanisms responsible for increased sodium reabsorption and
hypertension in obesity are still unclear. Two factors that might
contribute to increased tubular reabsorption of sodium in obe-
sity include activation of the renin-angiotensin system and
increased renal sympathetic activity [90, 91, 109]. Preliminary
studies in our laboratory indicate that plasma renin activity is
increased approximately twofold in obese dogs and that acute
or chronic sympathetic blockade produces a much greater
reduction in blood pressure in obese than in normal dogs
(unpublished observations). The quantitative importance of
these changes in contributing to increased sodium reabsorption
and to the rise in blood pressure associated with weight gain is
still unclear and is an important area for further investigation. In
addition, the mechanisms responsible for activation of the
renin-angiotensin system and sympathetic nervous system in
obese patients also will require further study.
Another factor that could contribute to increased tubular
reabsorption in obesity is altered intrarenal physical forces
associated with histologic changes. Preliminary histologic stud-
ies in kidneys from obese dogs reveal striking changes in the
renal medulla: marked increases in the number of cells, and
especially non-cellular matrix material between the tubules,
which appear to compress the tubules [109]. The matrix mate-
rial between the tubules stains with alcian blue and periodic
acid-Schiff (PAS), suggesting increased glycoprotein content.
These changes were observed only in the renal medulla, not in
the renal cortex. Since the kidney is surrounded by a tight
capsule with a low compliance, cell proliferation or matrix
deposition between the tubules could raise interstitial fluid
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hydrostatic pressure and cause tubular compression (Fig. 7).
Indeed, preliminary observations indicate that renal interstitial
fluid hydrostatic pressure is approximately 10 mm Hg higher in
kidneys of obese compared with normal dogs [1091. Although
small increases in renal interstitial hydrostatic pressure might
reduce tubular reabsorption, large increases could cause tubu-
lar compression which, in turn, could reduce tubular flow rate,
increase tubular transit time, and increase tubular reabsorption
[110]. A tendency toward tubular collapse would especially be
expected in the loop of Henle, which normally is very disten-
sible. Because we found that renal interstitial hydrostatic pres-
sure is elevated to approximately 19 mm Hg in the kidneys of
obese dogs, the tubular pressure in the loop of Henle also must
be increased to this level to maintain flow in the tubule.
Increased pressure in the loop of Henle could occur as a
result of increased delivery to this site secondary to an increase
in GFR or to a reduction in proximal tubule reabsorption.
Preliminary studies indicate that proximal fractional reabsorp-
tion, estimated with the lithium clearance technique, is not
markedly altered in kidneys of obese dogs [109]. However,
GFR is increased by approximately 35% to 50% via mecha-
nisms that are not currently understood. One possible explana-
tion is that initial changes in renal medullary histology could
increase reabsorption in the ioop of Henle and that these
alterations in turn would reduce sodium chloride delivery to the
macula densa. This reduction would initiate compensatory
renal vasodilation, as well as increased renin secretion, both of
which have been observed in obese dogs [109]. Thus, obesity-
induced hypertension might be due, in part, to histologic
changes in the renal medulla that increase intrarenal pressures
and necessitate increased arterial pressure to maintain sodium
balance. Although preliminary studies suggest that similar
histologic changes occur in the renal medulla of obese humans
(Herrera G, personal communication), additional studies are
needed in humans to further document these abnormalities and
to determine their quantitative importance in causing hyperten-
sion.
In summary, although plasma insulin and blood pressure
might be correlated in some individuals, a cause-and-effect
relationship among insulin resistance, hyperinsulinemia, and
hypertension has not been clearly established. Only a few
studies of the long-term effects of insulin on blood pressure
regulation have been published, and most of these reports have
suggested that hyperinsulinemia per se cannot account for
obesity-induced hypertension. Further studies on the quantita-
tive importance of insulin resistance and hyperinsulinemia on
long-term blood pressure regulation in humans are needed. In
addition, other mechanisms that alter renal function and blood
pressure in obesity should be examined, particularly those that
cause a chronic increase in renal tubular sodium reabsorption
and shift of pressure natriuresis to higher blood pressures.
Questions and answers
Ms. CAROL STOLLAR (Dietitian, Frances Stern Nutrition
Center, New England Medical Center, Boston, Massachu-
setts): You used the term "high-fat" diet throughout your talk.
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Fig. 6. Steady-state relationship between mean arterial pressure and
urinary sodium excretion for non-obese adolescents (U, n = 18), obese
adolescents (, n = 60), and obese adolescents after weight loss (0, n
= 36). (Adapted with permission from Ref. 11.)
Fig. 7. Possible mechanisms by which altered renal medullary histol-
ogy associated with obesity could lead to increased total tissue pressure
in the kidney, increased tubular reabsorption, and chronic hyperten-
sion.
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You used beef tallow, which is a fairly saturated fat. Do you
know whether other fats behave the same way? Have you tried
others?
DR. HALL: We have not had the opportunity to do those
studies. There is some evidence from rat studies that high
caloric intake in the form of fructose or sucrose causes hyper-
tension [111, 112]. However, we have not studied other high-fat
or high-carbohydrate diets in dogs.
DR. ANDREW KING (Division of Nephrology, New England
Medical Center): I'm intrigued by the histologic changes in the
medulla. Is there any evidence that obese individuals have
concentrating and diluting disorders or other evidence of med-
ullary dysfunction?
DR. HALL: Not that I am aware of. The obese dogs that we
studied concentrated their urine, but not to a maximal level.
Their average urine osmolality was approximately equal to that
of normal dogs. But if we subject them to 24 hours of vasopres-
sin infusion to quantitate maximal concentrating ability, they do
not concentrate their urine as well as normal dogs do (unpub-
lished observations). I don't know whether similar studies have
been done in obese humans.
DR. RICHARD LAFAYETTE (Division of Nephrology, New
England Medical Center): Hyperlipidemia is a frequent compo-
nent of this syndrome. Have you examined this dyslipidemic
component in terms of its association with changing the hor-
monal milieu or directly causing vascular injury within the
medulla?
DR. HALL: No, we have not. That is a good suggestion.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): In the early part
of your talk, you commented on the use of the glucose clamp
technique. In those studies, you're obviously giving lots of
glucose. Does the increase in glucose trafficking through the
body have anything to do with the observed decrease in blood
pressure?
DR. HALL: I think it does. The increased uptake of glucose,
by activating local vasodilatory mechanisms, might be respon-
sible for the peripheral vasodilation and the transient fall in
blood pressure with insulin and glucose infusions. However,
there is also evidence that insulin dilates isolated blood vessels.
At present, it's difficult to quantitatively assess the contribution
of the increased glucose uptake and of direct vascular actions of
insulin in mediating the decrease in blood pressure associated
with chronic insulin infusion.
DR. HARRINGTON: I have a second, unrelated question. Are
there good measurements of total-body sodium in type-I dia-
betics soon after the diagnosis has been made—when the GFR
is supranormal? Is total-body sodium balance positive? My
understanding is that these patients are not sodium overloaded.
Could you comment on this?
DR. HALL: We have been talking about type-Il diabetics, who
tend to have high GFRs and sodium retention, as we observed
in these obese dogs. Type-I diabetics also have increased GFRs
in the early phase, but as the GFR starts decreasing, they may
retain sodium. Obviously, if they have an increase in GFR, they
also must have an increase in tubular reabsorption. A few years
ago, we studied the effects of hyperglycemia per se as a
mechanism for increased GFR in type-I diabetes [113]. Our
studies suggested that hyperglycemia might increase GFR, in
part, by a tubuloglomerular feedback mechanism [113]. In the
absence of tubuloglomerular feedback, hyperglycemia did not
raise the GFR [113]. To get back to the obesity model, there are
some similarities with type-I diabetes. One possible explanation
for the high GFR in obese animals is an increase in reabsorption
in the loop of Henle prior to the macula densa.
DR. NICOLAOS E. MADLAS (Chief, Division of Nephrology,
New England Medical Center): In many situations in which
there is interaction of various systems with opposing effects,
one is able to demonstrate the possible pathophysiologic role of
a given system through the use of inhibitors. I was wondering
whether somatostatin could be used in chronically obese ani-
mals—dogs and rats—to probe whether insulin might have a
hypertensive role, an effect that might be masked because of the
concomitant activation of other systems.
DR. HALL: We've tried that in preliminary studies in obese
dogs. We gave somatostatin for 24 hours; we limited adminis-
tration to 24 hours because somatostatin is very expensive. We
found no change in blood pressure (unpublished observations).
Some work has been done recently in insulin-resistant humans
and rats. In one study by Carretta et al, somatostatin was given
for several hours to obese hypertensive patients; their blood
pressure decreased a few mm Hg [114]. However, because
somatostatin has many other effects besides inhibiting insulin
secretion, the results are not convincing. I know of no studies
that have examined the long-term effects of somatostatin on
blood pressure in obese hypertensive patients; if somatostatin
does chronically reduce blood pressure, it is important to
demonstrate that insulin replacement reverses the effect of
somatostatin.
DR. MADIAS: The plasma concentration of insulin that you
obtained in your infusion studies is more than sufficient to
enhance translocation of potassium into cells—muscle, liver,
and adipose tissue. The resultant hypokalemia could then affect
plasma renin activity, vascular resistance, and renal sodium
reabsorption. Was hypokalemia observed in your studies?
DR. HALL: Insulin can shift potassium from extracellular to
intracellular fluid. However, there were no major changes in
plasma potassium in our studies [82, 83]. Although plasma
potassium tended to decrease in some experiments, the changes
were small. I agree, however, that some of the renal changes
observed during insulin infusion could be related to transloca-
tion of potassium into the cells.
DR. AJAY SINGH (Division of Nephrology, New England
Medical Center): I'd like to ask you questions about the
epidemiology of this syndrome. First, does this syndrome of
hyperinsulinemia, obesity, and hypertension cluster in families?
Second, is there any evidence in twin studies of increased risk
for the syndrome? Third, are racial factors important?
DR. HALL: Yes, racial factors should be considered. For
example, in Mexican Americans, hyperinsulinemia and insulin
resistance often are not associated with hypertension. The
incidence of type-I! diabetes in Mexican Americans is very
high, and yet the incidence of hypertension is low. In contrast,
the relationship might be stronger in Caucasoids. Obviously,
these differences imply that genetic factors might be important.
I'm not aware of twin studies, but the abnormalities would be
expected to cluster in families because obesity clusters for
genetic and environmental reasons.
DR. RONALD D. PERRONE (Division of Nephrology, New
England Medical Center): I have two questions relating to the
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interstitial changes that you demonstrated. Are these changes
reversible with reduction of the high-fat diet?
DR. HALL: Yes, they appear to be reversible if the animals
return to their normal body weight. However, it took much
longer for them to return to normal body weight than for them
to become obese.
DR. PERRONE: My second question relates to this model: are
there other models of increased interstitial pressure? Is this a
known mechanism of hypertension? For example, interstitial
nephritis or nephrotic syndrome might cause interstitial edema
and tubular compression.
DR. HALL: That's a good question and one that we would like
to examine. We have one case, Dr. Guillermo Herrera's pa-
tient, in whom an interstitial cell tumor was associated with
severe hypertension (personal communication). However, I
know of no published studies that have directly tested whether
renomedullary compression and increased interstitial fluid hy-
drostatic pressure can cause chronic hypertension.
DR. HARRINGTON: Could you tell us precisely how you
measure renal interstitial pressure? What is the coefficient of
variability? Did you measure it acutely only? Can you measure
it chronically? Do you have any simultaneous measurements of
intratubular pressure?
DR. HALL: We measured renal interstitial fluid hydrostatic
pressure using the implanted capsule technique designed by
Cobern Ott at the University of Mississippi and later micro-
adapted by Frank Knox's group at the Mayo Clinic. We have
not measured renal interstitial fluid pressure chronically during
the development of the hypertension, only at the terminal phase
after the animals have established hypertension. We implanted
the capsules and measured the interstitial fluid pressure acutely.
Measurements in different dogs vary, as you might expect,
because some dogs gain more weight and become more hyper-
tensive than others. We do not yet have measurements of
intratubular pressures.
Da. MADIAS: You suggested that the intratubular pressure
might be greater than 20 mm Hg in these animals. Shouldn't this
change affect glomerular filtration? If I understood you, GFR is
increased from normal in these animals.
DR. HALL: We have not measured intratubular pressure, but
it must be at least 20 mm Hg for the tubules to remain open if
renal interstitial fluid hydrostatic pressure is approximately 20
mm Hg. Tubular pressure could increase because of increased
resistance to flow in the tubule and increased GFR. As I said
earlier, the increase in GFR could be a compensation for
increased tubular reabsorption. There are two ways by which
tubular flow rate could be reestablished if there is an increase in
reabsorption in the loop of Henle: by increasing GFR or by
decreasing proximal reabsorption. Our preliminary data do not
indicate an inhibition of proximal reabsorption. I would suggest
that a rise in tubular pressure could result from increased GFR
in combination with the increased resistance to tubular flow.
DR. MADIAS: I was wondering whether the histologic changes
that you observed in the renal medulla of obese dogs are present
in the obese Zucker rat.
DR. HALL: The obese Zucker rat has multiple renal abnor-
malities, including glomerular damage. I'm not aware of de-
tailed studies of the renal medulla in obese Zucker rats.
DR. ANDREW S. LEVEY (Division of Nephrology, New Eng-
land Medical Center): I'm interested in the cause of decline in
total peripheral resistance with obesity. With insulin infusion, it
appears to be due to increased metabolic rate. Is the cause the
same in obese dogs? Second, is there renal vasodilation?
DR. HALL: Yes, there is renal vasodilation. Rocchini also has
shown that obesity is associated with forearm vasodilation in
humans [105], and we found that renal blood flow is elevated
35% to 50% in obese dogs [90, 109]. My guess is that coronary
blood flow also is elevated because of a greater work load on the
heart. Although we have not studied the mechanisms responsi-
ble for the increased cardiac output in obese dogs, the increased
metabolic rate of various tissues could play an important role.
DR. LEVEY: A followup question is, could the decline in renal
vascular resistance cause the increased sodium reabsorption?
DR. HALL: Renal vasodilation and increased GFR would not
lead to sodium retention and increased fractional sodium reab-
sorption, as we observed in obese dogs [90, 109]. In fact, renal
vasodilation, as a primary change, should cause natriuresis and
sodium loss. The sodium retention observed in obese dogs,
despite renal vasodilation, can be explained, however, if the
renal vasodilation and increased GFR occur as a compensation
for a primary increase in tubular reabsorption.
Da. ANDREW KING (Division of Nephrology, New England
Medical Center): If there is a decrease in total peripheral
resistance, is the mechanism of hypertension related to an
increase in cardiac output due to volume expansion?
DR. HALL: The cardiac output increases in obese dogs. If you
index cardiac output according to body weight, it is not ele-
vated. However, indexing cardiac output to body weight might
not be appropriate because much of the increased weight is fat,
and blood flow in fat is not as great as flow in many other
tissues. Blood flow in skeletal muscle, kidneys, and cardiac
tissue is likely to be increased. In addition, there is expansion of
extracellular fluid volume and marked renal sodium retention,
which we believe play an important role in causing obesity-
induced hypertension.
DR. KING: I'm intrigued by the renal findings of increased
GFR and renal plasma flow in these patients. These findings are
not the footprints of either norepinephrine or angiotensin II.
You believe that this glomerular hemodynamic profile is due to
a decrease in tubuloglomerular feedback. Have you done any
stop-flow studies or assessed the activity of TGF in these
animals?
DR. HALL: No, we have not done those studies. We believe
that tubuloglomerular feedback is a possible explanation for the
increased GFR. Reduced distal tubular sodium chloride deliv-
ery, caused by increased reabsorption at a site prior to the
macula densa, would be expected to cause a compensatory rise
in GFR. Increased GFR also could occur via a change in
sensitivity of the macula densa mechanism. We haven't had the
opportunity to test this hypothesis yet. Micropuncture is diffi-
cult in the dog, but we do plan to do these experiments.
DR. MADIAS: I was intrigued by the fact that in your studies,
insulin infusion in rats increased systemic blood pressure sig-
nificantly. It is of interest that the spontaneously hypertensive
rat (SHR) displays insulin resistance [115] and that the stimu-
latory effect of insulin on the proximal tubule Na/H ex-
changer is greater in the SHR compared with the Wistar-Kyoto
rat, the normotensive counterpart [116]. Studies show that
some antihypertensive medications might affect insulin resis-
tance. Thiazides and beta blockers have been shown to worsen
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insulin resistance, whereas angiotensin-converting enzyme in-
hibitors and alpha1 blockers improve insulin sensitivity [117].
Could you comment on the possible mechanism of these
effects?
Da. HALL: I don't have a good explanation. Several concepts
have been proposed. Dr. Stevo Julius has suggested that insulin
resistance might be caused by increased peripheral vascular
resistance and vascular rarefaction, which reduce tissue deliv-
ery of insulin and glucose, and impair glucose uptake, espe-
cially in skeletal muscle [38]. If that concept were correct,
you'd expect blood flow in peripheral tissues to be reduced in
these insulin-resistant individuals; this is not the case. In obese,
insulin-resistant dogs and in obese humans, skeletal muscle
blood flow is elevated [1051. If the enhancement of insulin
sensitivity by converting enzyme inhibitors is as simple as
vasodilation, other vasodilators should work as well as convert-
ing enzyme inhibitors; this does not seem to be the case. We
don't have a good explanation for why converting enzyme
inhibitors improve insulin sensitivity.
DR. MADIAS: Did I understand you to say that in obese
individuals, insulin doesn't have as much of a vasodilatory
effect on peripheral tissues? To what extent might this defect
contribute to insulin resistance and compensatory hyperinsu-
linemia? Also, is this defect present in hypertensive, non-obese
individuals?
DR. HALL: Yes. The vasodilatory effect of insulin is attenu-
ated in obese, insulin-resistant patients and in obese dogs [1021.
The role of this defect in contributing to insulin resistance is
unknown. It is possible that insulin resistance (for example,
impaired insulin-stimulated glucose uptake in skeletal muscle)
is responsible for the impaired vasodilatory effect of insulin. If
the peripheral vasodilatory effect of insulin is linked to stimu-
lation of tissue glucose uptake and increased tissue metabolism,
then insulin resistance should be associated with an impaired
vasodilatory response to insulin. There is evidence that some
lean hypertensive patients are insulin resistant [24], but the
vasodilatory action of insulin in these individuals has not been
extensively studied.
DR. HARRTNGTON: Your studies on salt-induced hypertension
were done in your obese dog model. What percentage weight
loss is required to achieve eradication of salt-induced hyperten-
sion?
DR. HALL: We have not done that in the dog. Salt-sensitivity
of blood pressure has been studied in obese humans by Roe-
chini et a! [11]. In that study, salt sensitivity of blood pressure
was reversed by weight loss, even though the patients did not
return to ideal body weight.
DR. LEVEY: Did the change in blood pressure parallel the
change in dietary intake or the change in weight?
DR. HALL: In our obese dogs, blood pressure paralleled the
increase in body weight.
DR. KING: In your studies, plasma renin activity and norepi-
nephrine are increased, and vasodilation occurs. Do these dogs
manifest a resistance to All? For instance, ii you infuse All in
these animals, do they show an equivalent hypertensive re-
sponse? Is there evidence of decreased receptors?
DR. HALL: We have not performed those studies yet.
DR. KING: Do you think the sympathetic nervous system is a
primary signal for the All?
DR. HALL: When we infused alpha- and beta-adrenergic
blockers for 7 days in obese dogs, we did not find any changes
in plasma renin activity (unpublished observations). This ob-
servation suggests that another stimulus for increased renin
secretion, other than the sympathetic nervous system, might
exist. One possibility is that renin secretion is increased by a
macula densa mechanism that, in turn, is activated by increased
sodium chloride reabsorption in the loop of Henle.
DR. LAFAYETFE: Vasodilation in this model could be due to
some other circulating factor not yet examined. Is there an
increased metabolic activity present in skeletal or heart muscle
or in the kidney that might be responsible for "work-load"
vasodilation? Have you or other investigators looked at total-
body metabolic rate in the study animal or obese humans?
DR. HALL: We haven't done that in these animals. Oxygen
consumption and cardiac output are both elevated in obesity,
suggesting increased metabolic rate. It is likely that increased
metabolic rate is a stimulus for vasodilation in some tissues,
such as skeletal muscle. However, it is also possible that
circulating factors could contribute to peripheral vasodilation.
Atrial natriuretic factor tends to be elevated, but it is not a very
good vasodilator in the kidney. As I said before, the macula
densa feedback could contribute to renal vasodilation and
increased GFR.
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